Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura

Abstract

Neurological symptoms related to microthrombosis are the hallmark of acute manifestations of acquired thrombotic thrombocytopenic purpura (TTP). Despite the achievement of hematological remission, patients may report persisting neurological impairment that affects their quality of life. To assess the long-term neuropsychological consequences of acute TTP, we recruited 35 acquired TTP patients (77% females, median age at onset 41 years, interquartile range: 35–48) regularly followed at our out-patient clinic of thrombotic microangiopathies in Milan (Italy) from December 2015 to October 2016. Patients underwent a psychological evaluation of memory and attentional functions, emotional wellbeing and health-related quality of life at least three months after their last acute TTP event (median 36 months, interquartile range: 17–54). During the psychological consultation, 17 patients (49%) referred persisting subjective neurological impairment in the frame of a remission phase, with at least one symptom as disorientation, loss of concentration, dizziness, lack of balance, headache and diplopia. Neuropsychological assessment revealed lower scores than the Italian general population pertaining to direct, indirect and deferred memory. A higher degree of impairment of memory domains was found in patients with neurological involvement at the time of presentation of the first acute TTP episode. Anxiety and depression were detected in seven (20%) and 15 (43%) patients, respectively. Health-related quality of life was lower than the Italian general population, with mental domains more impacted than physical domains (mean difference 58.43, 95% confidence interval: 71.49–45.37). Our study demonstrates compromised memory and attention functions, persisting anxiety/depression symptoms and a generally reduced quality of life in patients recovering from acute acquired TTP. New clinical strategies should be considered to improve these symptoms.

Introduction

Thrombotic thrombocytopenic purpura (TTP) is a rare multisystem microangiopathy with fluctuating signs and symptoms. Its mortality rate can reach 90% when patients are left untreated, but it is reduced to 10% if patients are properly treated in the first 24 hours after diagnosis. Recovery is usually complete, but with a risk of relapse and the uncommon occurrence of persistent neurologic, cardiac and renal abnormalities.1 After recovery, despite normal physical examination and laboratory data, many patients complain of difficulties with memory, headache, loss of concentration and endurance, as expressed at patient support group meetings. Some attempts to quantify those neurological deficits in acquired TTP patients have been made in the context of small observational studies, but without taking into account a whole assessment of cognitive, emotional and health-related quality of life (HrQoL) dimensions.32 Cognitive domains required for complex attention, concentration skills and high level memory functions may be involved in patients with TTP due to diffuse microvascular subcortical lesions, similarly to neurologically normal individuals with untreated hypertension, sickle cell disease and multi-infarct dementia. Two widely accepted measures to evaluate HrQoL are the Short-Form 36 (SF-36)4 and the EuroQol 5D (EQ-5D).5 They are self-reported scales providing a numerical score to identify the level of perceived health status. For their generic nature, the SF-36 and the EQ-5D are frequently used in chronic conditions (e.g. hemophilia) and are applicable to many diseases.

With this background and gaps of knowledge, we set up a study in order to investigate persistent cognitive abnormalities, emotional wellbeing and quality of life in patients who had recovered from an acute episode of acquired TTP. We also analyzed whether or not the presence of neurological involvement during the acute phase of TTP or severe ADAMTS13 deficiency during disease remission were related to persistent neurocognitive defects. Finally, we investigated whether there was an association between the emotional status of the patients and their quality of life.

Methods

Patients

We performed a cross-sectional study of 35 patients with acquired TTP regularly followed at our out-patient clinic of thrombotic microangiopathies in Milan (Italy). Patients were enrolled at least three months after their last acute TTP event (median time of 36 months, interquartile range [IQR]: 17–54) from December 2015 to October 2016, when they underwent a comprehensive neuropsychological evaluation including memory and attentional functions, emotional wellbeing and HrQoL. Demographic and clinical variables were recorded, including age, sex, ethnicity, job status, level of education, clinical and biochemical data at the time of acute TTP (neurological involvement, platelet count and haemoglobin level at presentation, number of plasma exchange procedures required to attain remission), and plasma ADAMTS13 activity levels at the time of the neuropsychological assessment (± three months). Enrolment criteria are described in the Online Supplementary Table S1.

Written informed consent was obtained from all subjects with approval of the Ethics Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in accordance with the Declaration of Helsinki.

Neurocognitive, emotional and HrQoL assessments

Neurocognitive and psychological assessments were administered by a board-certified psychologist in the standardized fashion in the frame of a single assessment session, which required approximately 1 hour to be completed, and included a test battery measuring two major cognitive domains, memory and attention,86 the Hamilton Depression (HAM-D)9 and Anxiety (HAM-A)10 rating scales for emotional wellbeing, and the Short-Form (SF) 364 form for HrQoL (Online Supplementary Material and Methods and Online Supplementary Table S2).

Statistical analysis

Descriptive statistics were used for demographic, clinical and laboratory characteristics. Categorical variables were expressed as counts and percentages, continuous variables as means or medians with standard deviation (SD) or IQR. With regards to neuropsychological and HrQoL analyses, each subject’s raw score on each test was converted to a standardized score based on normative data generated from the value of the normal population according to the subject’s age and education level, as appropriate.1511 Standardized scores of TTP patients were then compared with norm-referenced data from the Italian population1511 by calculating the difference of means with 95% confidence intervals (CI) using unpaired and paired t-tests. Similarly, difference of means with 95% CI from unpaired and paired t-tests were used to compare neurocognitive assessment results in acquired TTP patients with and without neurological manifestations during the first acute episode of TTP, and with and without reduced ADAMTS13 activity during disease remission, close to the neuropsychological evaluation. For this analysis, an ADAMTS13 activity cut-off of 45% was used (i.e. the lower limit of the normality range in our ADAMTS13 activity assays). With regards to HrQoL, a standardized score of 50 was considered the cut-off for an acceptable quality of life.1615 Finally, non-parametric correlation analyses were performed to evaluate the relationship between the results of emotional wellbeing tests and those of neurocognitive assessments or aggregated HrQoL scales.

Statistical analyses were performed by SPSS, release 25.0 (IBM Corp., Armonk, NY, USA), and GraphPad Prism, version 7.03 (GraphPad Software, La Jolla, CA, USA).

Results

Between December 2015 and October 2016, 41 acquired TTP patients were approached for participating in the study during a follow-up visit at our out-patient clinic of thrombotic microangiopathy. Of them, one patient refused to participate and one patient was excluded owing to a pre-existing psychiatric disease. Four were not constantly attended at our center, and therefore they were excluded from the study. Thus, 35 patients were included in the study and underwent psychological tests and neurocognitive examinations (see the Online Supplementary Material and Methods). Patient characteristics are reported in Table 1. All but one patient were Caucasian, with a female to male ratio of about 3:1 and a median age at TTP onset of 41 years (IQR: 35–48). At the time of neuropsychological evaluation, 10 (29%) of 35 patients had suffered from recurrent TTP bouts. 22 patients (63%) presented with neurological signs and symptoms at presentation of the first acute TTP episode (including coma [n=2], focal neurological signs [n=12], personality changes [n=2], transient ischemic attack [n=4], seizures [n=1], stroke [n=3]). During the psychological consultation, 17 (49%) patients reported persisting subjective neurological impairment in the remission phase, with at least one symptom as disorientation, loss of concentration, dizziness, lack of balance (unable to control and maintain the body position all the time) headache, and diplopia.

Table 1.Demographic and clinical characteristics of 35 thrombotic thrombocytopenic purpura patients included in the study. Clinical and laboratory data pertain the first acute thrombotic thrombocytopenic purpura episode.

Results of neurocognitive assessment

At the digit span test, 25 (71%) and 23 (66%) patients had a scoring lower than the mean of the general population in direct (mean difference −1.26; 95% CI: −1.64--0.87]) and backward (mean difference −1.49; 95% CI: − 2.02--0.96) memory, respectively (Table 2). Similarly, lower scores in TTP patients were observed in the Rey List tests for both direct (mean difference −5.87; 95% CI: 8.57- -3.17) and deferred memory (mean difference −1.67; 95% CI: −2.32--1.02).

Table 2.Descriptive statistics of neuropsychological tests in acquired thrombotic thrombocytopenic purpura patients and mean values of the Italian general population.

With regards to the attention domain, TTP patients were slower in performing the trail making B test (sustained and divided attention) in comparison with the general population (mean difference 65.09 seconds; 95% CI: 47.23–82.94). Conversely, patients were slightly faster in performing the trail making A test, which measures focused attention (mean difference −10.63 seconds; 95% CI: 15.81--5.44).

When we analyzed scores of neurocognitive assessments in patients with and without neurological signs and symptoms at presentation of the first acute TTP episode, we observed a higher degree of impairment in the memory domains of the first group of patients in 3 of 4 memory tests (digit span [direct]: mean difference −0.78; 95% CI: −1.54--0.02; digit span [backward]: mean difference 0.90; 95% CI: −1.96--0.17]; Rey word list [deferred]: mean difference −1.39; 95% CI: −2.65--0.13) (Table 3).

Table 3.Descriptive statistics of neuropsychological tests in acquired thrombotic thrombocytopenic purpura (TTP) patients with and without neurological manifestations at onset of the first acute TTP event.

No differences in neuropsychological assessments were found between patients with ADAMTS13 activity levels during remission below and above 45% (Table 4).

Table 4.Descriptive statistics of neuropsychological tests in acquired thrombotic thrombocytopenic purpura patients with and without ADAMTS13 deficiency next to the psychological evaluation.

Results of emotional assessment

TTP patients presented a mean level of anxiety with the HAM-A of 9.6 (SD=8.1) and a mean level of depression with the HAM-D of 7.4 (SD=5.7). The presence of clinical anxiety (HAM-A score >13) was detected in seven (20%) of interviewed patients, while the presence of clinical depression (HAM-D score >7) was present in 15 (43%) of them. All seven patients with clinical anxiety presented concomitant clinical depression. Five (14%) patients showed a severe anxiety (HAM-A score >24) and five (14%) a medium level of depression (HAM-D score >18). No patients presented severe levels of depression (HAM-D score >24).

Among the type of disturbances, we found that the most impaired domains in HAM-D were “work activities” (n=10, 77%), “depressed mood” (n=8, 60%) and “early insomnia” (n=4, 27%) while in HAM-A there were “intellectual symptoms” (i.e. difficulty in concentration and poor memory) (n=6 82%) and “tension” (n=4, 54%).

At correlation analysis, better wellbeing was associated with better memory function (the sign of the correlation coefficient is negative because of the opposite interpretation scale of the two measurements): HAM-A test versus: digit span direct Spearman rho −0.472, P=0.004; digit span backward Spearman rho −0.597, P<0.001; Rey list direct Spearman rho 0.310, P=0.075; Rey list recall: Spearman rho −0.432, P=0.011; HAM-D test versus: digit span direct Spearman rho −0.474, P=0.004; digit span backward Spearman rho −0.594, P<0.001; Rey list direct Spearman rho 0.357, P=0.038; Rey list recall: Spearman rho −0.499, P=0.003.

Results of HrQoL assessment

Table 5 displays the mean scores of the SF-36 assessments for each of the eight domains by physical and mental components: physical activity (PA), role physically (RP), bodily pain (BP), general health (GH), vitality (VI), social functioning (SF), role emotional (ER) and mental health (MH). Acquired TTP patients showed lower normalized scores than the Italian reference sample14 in all scales but physical activity. With regard to the physical components, the most impacted area was the physical role, with a mean score of 57 (median 55; range: 40–85) and 11 patients (31%) with scores below 50. With regard to the mental components, emotional role was the most compromised, with a mean score of 43 (median 43; range: 30–56) and 22 patients (63%) with scores below 50. Overall, the mental dimension was more affected than the physical dimension, with the mental component score MCS-36 (equivalent to the sum of MH, ER, SF and VI scores) lower than the physical component score PCS-36 (equivalent to the sum of PA, RP, BP and GH scores) by almost 60 points (mean difference −58.43; 95% CI: −71.49--45.37) and 15 (43% of patients pertaining to the MCS-36) versus four (11% of patients pertaining to the PCS-36) patients with scores below 50, the commonly accepted cut-off for an acceptable quality of life.1615

Table 5.Descriptive statistics of health-related quality of life components in acquired thrombotic thrombocytopenic purpura patients and in Italian reference individuals.

Finally, at correlation analysis, the better the mental component score of the HrQoL survey was, the better were the results of emotional wellbeing assessments, especially the anxiety evaluation (MCS-36 vs. HAM-A test: Spearman rho −0.358, P=0.035; MCS-36 vs. HAM-D test: Spearman rho −0.316, P=0.064).

Discussion

Neurological signs and symptoms of acute TTP are mainly transient, brief and resolve with remission of the acute phase. Our study demonstrates persisting neurological, neuropsychological, emotional and HrQoL impairments in TTP patients even years after the acute phase.

During the remission phase, TTP patients showed a significant impairment in memory domains (direct, backward and deferred memory) when compared with the general population. This memory impairment was positively associated with the presence of neurological symptoms during the acute phase of the disease, as shown by the comparison between patients with and without neurological involvement during the first acute TTP event. Attention domains were also affected, but they were unrelated to neurological involvement during the acute phase. Our results are in line with previous findings by Kennedy et al. in 24 acquired TTP patients from the Oklahoma Registry, who performed significantly worse than the US reference population in both attention and memory functions.173 Conversely, at variance with our results, previous studies did not report an association of neurocognitive impairment with the occurrence of neurological manifestations at the time of the acute TTP event,183 although a trend towards a worse mental performance was detected in German patients with neurolog ical symptoms compared with patients with no neurological symptoms (median of FLei mental performance score: 45 [IQR: 15–65] vs. 31 [IQR: 13–40], Mann-Whitney U test P=0.193).18 It is worth-noticing that the prevalence of relapsing TTP cases were higher in patients with than without neurological symptoms during the first acute event (41% vs. 8%). Unfortunately, the low sample size did not allow us to discriminate the effects of these two factors.

Beside cognitive problems, we detected clinical anxiety and depression in 20% and 43% of interviewed patients. An even higher prevalence of depression symptoms in acquired TTP patients was reported in two US and one German cohorts (59%,17 81%,19 and 73%,18 respectively), which included also cases of major depression (29%,18 37%,19 and 14%).18 However, a pre-existing diagnosis of depressive disorder was not an exclusion criterion in these studies, which may partly explain the differences in the observed prevalence. In our study, the results of anxiety and depression tests were negatively correlated with scores of neurocognitive assessments, indicating that patients with symptoms of psychologic distress also had more pronounced cognitive defects. This is consistent with the findings of Falter and colleagues,18 who reported a strong correlation between an impaired mental performance and the severity of depression in 84 TTP patients.

It is interesting to compare our results with other cardiovascular and neurovascular diseases. High percentage of cognitive impairment were also found in patients after acute coronary syndrome (16% of patients),20 stroke (one-third of the sample examined),21 and after a transient ischemic attack (TIA) (more than a third of patients).22 After TIA, also depressive symptoms were found as prevalent as 34%.23 However, there are important differences between these studies and ours. First, the evaluation of cognitive decline and depression were generally made during the acute phase and in patients older than ours.23 Second, the literature mainly highlights a major deterioration at the level of functional abilities in daily life activities, especially in stroke patients. Finally, different tests were performed and different cognitive domains (e.g. language) evaluated, making any comparison difficult. We also found an overall impaired quality of life compared with the general population. In the HrQoL domains, mental components were more impaired than physical components, suggesting that the condition determines a considerable emotional burden, probably related to its course of intermittent relapse and remission phases. Indeed, the HrQoL mental domain was negatively affected by the presence of clinical anxiety and depression in our patients. Our findings are consistent with those of Lewis et al.2 and Cataland et al.24 although they reported a greater impact of acquired TTP on the physical component of the HrQoL,2 and on both the mental and the physical component.24

We believe that our findings have clinical relevance for the management of TTP patients. Clinicians should be aware of the association between neurological manifestations during the acute TTP episodes and long-term impaired neuropsychological abilities. They should put attention on signs and symptoms of neurological impairment during the remission phase and consider early signs of anxiety and depression in order to improve the quality of life of TTP patients.

Our study has limitations. First, the neurocognitive and emotional status of the patients and their quality of life before their first episode of TTP was not objectively evaluated. However, patients did perceive and referred at the time of the psychological consultation a worsening of their conditions after TTP diagnosis. Second, the evaluation of neurological and cognitive functions abnormalities observed in TTP patients in the remission phase and far from the clinical manifestations of acute TTP were not supported by instrumental neurofunctional analysis such as functional magnetic resonance imaging, which might be needed to assess the aforementioned alterations at the organic level. Third, we included patients with a history of a single acute TTP event but also patients with relapsing TTP, rendering our study population heterogeneous (in order to exclude potential comorbidities only primary TTP patients should be evaluated). However, the occurrence of multiple TTP episodes was never found to be associated with neurocognitive, emotional or HrQoL assessments in any previous study.2418173 Fourth, the tests performed to evaluate clinical anxiety and depression, despite being well-validated tools, can only be suggestive of a psychiatric diagnosis, which indeed can only be confirmed by a proper psychiatric interview. Fifth, despite the relatively large sample size for a rare disease, numbers in some analyses are small, leading to statistical uncertainty and wide CI. This is a problem of any study in the field of rare diseases, and stimulate more efforts to promote collaboration between centers. Finally, the design of our study is crosssectional and, thus cannot provide risk estimates and data about predictive factors. On the other hand, as far as we know, our study is the most comprehensive investigation on TTP patients, including clinical, cognitive, emotional and HrQoL assessment.

In conclusion, we demonstrated that, despite successful treatment with plasma exchange and immunosuppressive therapy in the acute stage of the disease, patients with TTP suffer from long term neurological sequelae even years after the acute phase. TTP patients with neurological involvement at the first acute episode seem to be at higher risk of developing memory dysfunction. Furthermore, TTP patients have increased levels of anxiety and depression, which negatively affect their quality of life. A faster improvement of the acute state of the disease by novel drugs might have a role in this process and further studies are required to solve this question.

Footnotes

• ↵* SR and IM contributed equally as co-first authors.
• Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/7/1957

• Received May 17, 2019.
• Accepted September 19, 2019.